Techcyte adds elea’s AI pathology documentation to Fusion

Techcyte is integrating eleaDNAi into Techcyte Fusion to let pathologists generate structured, coded reports inside the diagnostic workspace. The partnership aims to cut documentation friction and keep final sign-out under the physician’s control.

Why it matters: - Pathologists can document diagnoses without leaving Techcyte Fusion, which may reduce workflow friction and duplicate data entry. - The integration is designed to turn spoken assessments into structured pathology reports that can flow into downstream laboratory systems. - Techcyte and elea are positioning the partnership as part of a broader push toward an open, connected pathology ecosystem.

What happened: - Techcyte announced the availability of eleaDNAi inside Techcyte Fusion on Aug. 13, 2026. - eleaDNAi is elea’s AI-native pathology documentation technology. - Techcyte Fusion is the company’s digital pathology platform for anatomic and clinical pathology. - The integration places elea’s documentation intelligence directly in the diagnostic workspace.

The details: - eleaDNAi is built for pathology and goes beyond standard transcription. - The system converts a pathologist’s real-time verbal assessment into structured, coded documentation. - Pathologists can generate documentation, including synoptic documentation, with a voice command or a single click. - The platform supports interoperability with downstream laboratory systems. - Pathologists can review and edit the generated documentation before final sign-out. - The integration expands eleaDNAi beyond elea Lab, elea’s AI-native pathology information system. - The companies said the goal is to make the technology available within third-party pathology platforms. - Techcyte said its platform is for Research Use Only in the United States.

Between the lines: - The partnership reflects a view that AI should augment pathologists rather than replace diagnostic judgment. - The workflow pitch is about keeping the pathologist in one system from assessment through documentation. - Bringing eleaDNAi into Techcyte Fusion may help both companies reach laboratories that do not use elea Lab. - “Pathology ultimately comes down to the diagnosis, and technology should make that moment easier, not more complicated,” Ben Cahoon, Techcyte’s chief executive officer, said.

What’s next: - Laboratories interested in the integration can contact Techcyte through the company’s website. - Techcyte and elea are likely to use the integration to expand access to AI-assisted pathology documentation across more labs. - elea said eleaDNAi will continue to be part of its broader open pathology ecosystem.

The bottom line: - Techcyte is embedding elea’s pathology-specific AI into Fusion to make report generation faster, more structured and more tightly connected to the pathologist’s workflow.